Skip to main content
. Author manuscript; available in PMC: 2020 Feb 13.
Published in final edited form as: Integr Biol (Camb). 2018 Jan 22;10(1):18–33. doi: 10.1039/c7ib00218a

Fig 6. Effect of VEGF-targeting antibodies on endothelial VEGFR signaling in vivo.

Fig 6.

(Top) Predicted values of pR2/R2 (A-C) and fold change in pR2 (D-E) in the PAD Calf Muscle on Day 6 following treatment with control (left), Anti-VEGF165b (middle) or a non-isoform-specific Anti-VEGF (right), as a function of the local fractional secretion of VEGF165b in the PAD Calf Muscle (x-axis) and the Main Body Mass (y-axis). (Bottom) Predicted changes in total endothelial surface VEGFR1 ligation (F-H) and fold change in surface VEGFR1 ligation (I-J) in the PAD Calf Muscle on Day 6 following systemic antibody treatment. Black indicates an increase in receptor activation, while red indicates a decrease.